News

BlogsPosts
Press Release
RepliCel’s Phase 1 Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints
Five-year safety data firmly establishes product safety and confirms ongoing clinical and product development strategy VANCOUVER,
BlogsPosts
Press Release
RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization
VANCOUVER, BC – March 7, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”
BlogsPosts
Press Release
RepliCel Life Sciences Announces Re-pricing of Warrants
VANCOUVER, BC – March 6, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector
VANCOUVER, BC – February 28, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”
BlogsPosts
Press Release
RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION
BlogsPosts
Press Release
RepliCel Announces European Patents for its Innovative Dermal Injector Technologies
RCI-02, RepliCel’s nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin
BlogsPosts
Press Release
Replicel Life Sciences Inc. Announces Brokered Private Placement
VANCOUVER, BC – February 7, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel Appoints Corporate Executive, Hugh Rogers to its Board of Directors
VANCOUVER, BC – February 3, 2017 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)
BlogsPosts
Press Release
RepliCel CEO Provides 2017 Forecast
After a year of restructuring, RepliCel poised for multiple clinical trial data announcements and completion
BlogsPosts
Press Release
The Jake Brown Show
Episode 10: SNY’s Taylor Rooks, Stylist Megan Wilson, Replicel’s Lee Buckler
BlogsPosts
Press Release
RepliCel Life Sciences Announces Closing of Private Placement
Completed Financing Positions RepliCel Through Upcoming Milestones VANCOUVER, BC – October 31, 2016 – RepliCel
BlogsPosts
Press Release
RepliCel Life Sciences Amends Terms of Private Placement
  NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION
BlogsPosts
Press Release
RepliCel Announces Debt Settlement
VANCOUVER, BC – September 27, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP)
BlogsPosts
Press Release
RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
VANCOUVER, BC – September 26 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP)
BlogsPosts
Press Release
RepliCel Life Sciences Announces Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION
BlogsPosts
Press Release
Replicel Life Sciences Share Consolidation Approved
Capital Structure Restructuring Expected to Lead to Financing and Milestones VANCOUVER, BC – August 9,
BlogsPosts
Press Release
Replicel Life Sciences Continues Restructuring with Share Structure Consolidation
VANCOUVER, BC – July 22, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel’s Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
VANCOUVER, BC – July 21, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)
BlogsPosts
Press Release
Replicel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price
VANCOUVER, BC – April 29, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel Life Sciences conducts formal consultation review with Japan’s PMDA and receives unprecedented review fee reduction
Japan’s Pharmaceuticals and Medical Devices Agency reviews RepliCel’s pre-clinical, quality, and manufacturing data for its

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.